A-Mycin250 mg

A-Mycin is a macrolide antibiotic used to treat a range of bacterial infections and, in specific clinical contexts, to promote gastric motility.

Established / FDA-approved uses

• Respiratory tract infections (e.g. community-acquired pneumonia, pertussis, streptococcal pharyngitis) caused by susceptible organisms
• Skin and soft tissue infections due to susceptible strains of Staphylococcus and Streptococcus
• Sexually transmitted infections, including uncomplicated urogenital, rectal, or chlamydial infections and early syphilis in penicillin-allergic patients
• Diphtheria (adjunct to antitoxin, and for carrier eradication)
• Legionnaires' disease

Guideline-supported / alternative uses

• Alternative agent for patients with penicillin allergy who require treatment of susceptible infections
• Prophylaxis against recurrent rheumatic fever in penicillin-allergic patients
• Prevention of bacterial endocarditis in penicillin-allergic patients undergoing certain dental/surgical procedures (per older guidance; consult current cardiology guidelines)

Off-label use

• A-Mycin is used off-label at sub-antibacterial doses as a prokinetic agent to improve gastric emptying in conditions such as diabetic gastroparesis, based on its motilin-receptor agonist activity. This use requires physician supervision.

Each tablet/capsule of Erythromycin contains Erythromycin (as base, stearate, ethylsuccinate, or estolate salt, depending on formulation) as the active ingredient, along with pharmaceutically acceptable excipients. Available oral dosage forms include film-coated tablets, delayed-release (enteric-coated) tablets, and oral suspension; topical formulations include gel, solution, ointment, and ophthalmic ointment.

A-Mycin is a macrolide antibiotic originally derived from Saccharopolyspora erythraea. It is used to treat susceptible bacterial infections of the respiratory tract, skin, and soft tissues, and serves as an alternative to penicillin in patients who are allergic to it. A-Mycin also has prokinetic effects on the gastrointestinal tract at lower doses, which has led to its use in certain motility disorders.

A-Mycin belongs to the macrolide class of antibiotics.

Erythromycin exerts its antibacterial effect by binding reversibly to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting bacterial protein synthesis by blocking translocation of aminoacyl transfer-RNA. Depending on concentration and organism, it is bacteriostatic or bactericidal. It has activity against many Gram-positive organisms (e.g. Streptococcus, some Staphylococcus), and certain Gram-negative and atypical organisms (e.g. Legionella, Mycoplasma, Chlamydia, Campylobacter, Bordetella pertussis).

Separately from its antibacterial action, Erythromycin acts as an agonist at motilin receptors in the gastrointestinal smooth muscle, stimulating gastric and small bowel motility - the basis for its off-label prokinetic use.

A-Mycin is administered orally as tablets, delayed-release tablets, or oral suspension, and is also available in topical and ophthalmic formulations for localized use. Oral doses are typically spaced evenly throughout the day (e.g. every 6-12 hours) to maintain effective blood levels. Take with a full glass of water; a full course must be completed even if symptoms improve early.

A-Mycin is a potent inhibitor of the CYP3A4 enzyme and can significantly raise blood levels of drugs metabolized by this pathway, with clinically important consequences:

• Statins (simvastatin, lovastatin): increased risk of myopathy/rhabdomyolysis - avoid combination or temporarily suspend statin therapy.
• Ergot alkaloids: risk of acute ergotism (vasospasm, ischemia) - contraindicated in combination.
• QT-prolonging drugs (e.g. terfenadine, astemizole, cisapride, pimozide, certain antiarrhythmics): increased risk of serious ventricular arrhythmias including torsades de pointes - contraindicated in combination (see Contraindications).
• Oral anticoagulants (warfarin): enhanced anticoagulant effect and bleeding risk - monitor INR closely.
• Digoxin: increased digoxin levels due to altered gut flora and reduced clearance - monitor for toxicity.
• Theophylline: reduced clearance and increased risk of theophylline toxicity - monitor levels.
• Benzodiazepines (triazolam, midazolam) and certain calcium channel blockers: increased sedation/hypotension due to reduced clearance.
• CYP3A4 inducers (e.g. rifampin) or other strong CYP3A4 inhibitors: may alter A-Mycin levels or effect.

Always inform the physician of all concurrent medications, including over-the-counter drugs and supplements, before starting A-Mycin.

Most side effects of A-Mycin are gastrointestinal and dose-related, reflecting its prokinetic activity.

• Common: abdominal pain/cramping, nausea, vomiting, diarrhea, epigastric discomfort.
• Less common: skin rash, urticaria, mild allergic reactions.
• Rare but serious: reversible cholestatic hepatitis/jaundice (especially with the estolate salt, more common with prolonged use), QT prolongation and ventricular arrhythmias (see Interactions/Precautions), reversible hearing loss (usually with high-dose or intravenous therapy), infantile hypertrophic pyloric stenosis in neonates exposed to A-Mycin, and Clostridioides difficile-associated diarrhea/pseudomembranous colitis.
• Very rare: anaphylaxis, Stevens-Johnson syndrome.

Seek medical attention promptly for severe or persistent diarrhea, yellowing of the skin/eyes, irregular heartbeat, or signs of an allergic reaction.

A-Mycin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. A-Mycin is generally considered among the macrolides with a longer history of use in pregnancy, but the estolate salt form specifically should be avoided in pregnancy due to an increased risk of maternal hepatotoxicity.

A-Mycin passes into breast milk in small amounts. It is generally considered compatible with breastfeeding by most references, but a physician should be consulted, particularly for prolonged use, and the infant should be monitored for GI upset or rash.

A-Mycin must be taken exactly as prescribed by a physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, to reduce the risk of antibiotic resistance.

• QT prolongation/cardiac arrhythmia: Use with caution in patients with existing QT prolongation, uncorrected electrolyte disturbances (hypokalemia, hypomagnesemia), bradycardia, or concurrent use of other QT-prolonging drugs; serious ventricular arrhythmias including torsades de pointes have been reported.
• Hepatic impairment: Use with caution, as A-Mycin is eliminated primarily via the liver; hepatotoxicity (cholestatic hepatitis) can occur, especially with the estolate salt or prolonged therapy.
• Gastrointestinal effects: Dose-related GI upset is common due to prokinetic activity; report severe or bloody diarrhea promptly, as it may indicate C. difficile-associated colitis.
• Drug interactions: Significant CYP3A4-mediated interactions exist (see Interactions); review all concurrent medications before starting.
• Myasthenia gravis: May exacerbate muscle weakness; use with caution.
• Infants: Association with infantile hypertrophic pyloric stenosis when used in early infancy; caregivers should watch for feeding difficulty or forceful vomiting.

Overdose of A-Mycin may cause severe gastrointestinal symptoms (nausea, vomiting, abdominal cramping, diarrhea), transient hearing loss, or cardiac rhythm disturbances (including QT prolongation) in susceptible individuals. There is no specific antidote. If an overdose of A-Mycin is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and gastric decontamination may be considered by a physician if presentation is early. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted oral suspensions of A-Mycin should generally be stored as directed on the label (some require refrigeration) and discarded after the labeled expiry period following reconstitution.

Renal impairment

No routine dose adjustment is generally required for A-Mycin in renal impairment, but caution and dose reduction may be considered in severe renal impairment, particularly at higher doses, due to potential ototoxicity risk.

Hepatic impairment

A-Mycin is contraindicated or requires caution and possible dose adjustment in patients with significant hepatic impairment, since it is concentrated in and excreted via the liver (see Precautions and Contraindications).

Elderly

Elderly patients, especially those with renal or hepatic impairment or on multiple medications, may be at higher risk of QT prolongation and drug interactions; use A-Mycin with caution and monitor closely.

Pediatrics

See Pediatric Uses.

The duration of treatment with A-Mycin depends on the indication, typically ranging from 5-14 days for most bacterial infections (e.g. 10 days for streptococcal pharyngitis, 14 days for pertussis), and may extend longer for certain conditions such as syphilis. The complete course prescribed by the physician must be finished even if symptoms resolve early, to reduce the risk of relapse and antibiotic resistance.

Some oral suspension formulations of A-Mycin (e.g. ethylsuccinate powder for oral suspension) require reconstitution with water prior to use. Add the specified amount of water to the dry powder in two portions, shaking well after each addition, to form the final suspension; follow the manufacturer's instructions and use the provided measuring device. Shake well before each use and store as directed.

Erythromycin is classified as a macrolide antibiotic.

Erythromycin inhibits bacterial protein synthesis by binding reversibly to the 50S ribosomal subunit of susceptible bacteria, preventing translocation of aminoacyl-tRNA and thereby halting peptide chain elongation. This action is bacteriostatic at usual doses and can be bactericidal at higher concentrations against highly susceptible organisms.

Category B

A-Mycin is approved for use in children for susceptible infections, including pertussis, streptococcal pharyngitis, and certain respiratory and skin infections, with dosing generally based on body weight (30-50 mg/kg/day in divided doses, not exceeding adult maximums). Safety and efficacy for some specific off-label uses (e.g. prokinetic use) have not been formally established in children and should only be used under specialist supervision. Use of A-Mycin in neonates has been associated with infantile hypertrophic pyloric stenosis; caregivers of infants under 2 weeks of age should be counseled about signs of pyloric stenosis (irritability with feeding, forceful vomiting) and advised to contact a physician promptly if these occur.